Peripheral arterial disease (PAD) occurs when leg arteries become narrowed or blocked by plaque. These blockages can result in severe pain for patients, limited physical mobility, and life-threatening non-healing leg ulcers. According to the American Heart Association, this condition affects approximately 8 to 12 million Americans. With only about 25 percent of PAD patients undergoing treatment, it is a disease that is largely under-diagnosed and under-treated. If left untreated, PAD can lead to critical leg ischemia, a condition where not enough blood is being delivered to the leg to keep the tissue alive. Total loss of circulation to the legs and feet can cause gangrene and lead to amputation.
High blood sugar, also known as hyperglycemia, occurs when the body does not produce enough insulin to turn blood glucose into energy.
Less than half of individuals with peripheral artery disease, which is a narrowing of arteries to the limbs, stomach and head, are treated with appropriate medications and lifestyle counseling. These findings highlight the need to improve the quality of care for this high-risk group of individuals.
Two immune responses are important for recovery after a heart attack -; an acute inflammatory response that attracts leukocyte immune cells to remove dead tissue, followed by a resolving response that allows healing.
Increased activity in a deep-lying region of the brain called the amygdala is associated with a higher risk of heart attack and stroke, according to a study published in The Lancet.
The amygdala is known to process emotions such as fear and anger and the finding sheds light on the possible mechanism by which stress can lead to cardiovascular disease (CVD), say the study authors.
Using technology adapted from NASA's Mars lander as part of a large-scale bedsore reduction program, over half of the 13 participating hospitals were able to eliminate the occurrence of new bedsores completely; an additional 3 hospitals achieved reductions ranging from 11% to 90%.
OrbusNeich has announced the launch of its latest generation Dual Therapy Stent (DTS), the COMBO Plus.
New guidelines for the treatment of peripheral artery disease (PAD), include recommendations on the use of antiplatelet therapy to reduce the risk of blood clots and statin drugs to lower cholesterol and advise PAD patients to participate in a structured exercise program.
A large national study has confirmed the value of high-intensity statin treatments for people with cardiovascular disease, according to researchers at the Stanford University School of Medicine.
Researchers at the University of North Carolina School of Medicine have found a major clue that may explain why some people sustain relatively little damage from strokes or heart attacks despite severe arterial blockages.
In an effort to determine if stem cell therapy can prevent or improve a condition called "diabetic foot" caused by poor blood flow in patients with diabetes, a team of researchers in China has found that transplanting human placenta-derived mesenchymal stem cells (MSCs) into rats modeled with diabetes can affect blood vessel growth, potentially improving blood flow and preventing critical limb ischemia (CLI), a condition that results in diabetic foot and frequently leads to amputation.
MILabs will provide an advanced U-SPECT4CT system to the Yale Translational Research Imaging Center (Y-TRIC) in New Haven-Connecticut, with support of an NIH Shared Instrument Grant for advancing their program in multimodality molecular and translational cardiovascular imaging research.
The short-term risk of developing cardiovascular disease following a first pregnancy is higher for women experiencing placental syndromes and a preterm birth or an infant born smaller than the usual size, a University of South Florida study reports.
A research advance from the Sanford Burnham Prebys Medical Discovery Institute and Stanford University could lead to new drugs that minimize the damage caused by heart attacks.
A first-in-human trial of an everolimus-eluting bioresorbable vascular scaffold has shown that the device can achieve a high 2-year patency rate and low 2-year target lesion revascularisation rate in patients with peripheral artery disease involving the external iliac artery and superficial femoral artery.
VentureMed Group, Ltd., a medical device company based in northwest Ohio, has received 510(k) clearance from the U.S. Food and Drug Administration for the commercial distribution of a new surgical device for treating peripheral artery disease (PAD).
The dangers of arterial thrombosis - the formation of blood clots that can block arteries and cause illness or death - can escalate through a vicious cycle of coagulation and inflammation.
Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapy products, today announced it has completed the planned enrollment of 150 patients in a global Phase II trial of its PLacental eXpanded (PLX)-PAD cells for the treatment of intermittent claudication (IC), a peripheral artery disease (PAD). The double blind, randomized, placebo controlled trial enrolled 50 patients since October 2015 in the U.S., Germany, Israel, and South Korea.
Rush Oak Park Hospital is the first hospital in the surrounding area to acquire and use a newly approved technology that allows vascular surgeons to see in real-time the plaque they are removing during an atherectomy, a minimally invasive procedure that helps treat peripheral artery disease (PAD).
Long-term results from the ENESTnd trial indicate a favourable risk-benefit profile for frontline use of nilotinib in patients within 6 months of chronic phase-chronic myeloid leukaemia diagnosis.
“Genomic medicine really needs deep learning,” these were the words of keynote speaker Brendan Frey, CEO Deep Genomics at RE-WORK’s Deep Learning in Healthcare Summit 2016.